Drug intelligence / Profile preview

MRG004A

Development stage: Phase 3
Lead developer: Lepu Biopharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MRG004A is an investigational **tissue factor-targeting antibody-drug conjugate** developed by Lepu Biopharma and Shanghai Miracogen for tissue factor-positive advanced solid tumors. The ADC uses a monoclonal antibody directed against tissue factor to deliver the microtubule-disrupting payload monomethyl auristatin E into tumor cells. It uses GlycoConnect site-specific conjugation technology and HydraSpace technology, with a reported drug-to-antibody ratio of 3.8. MRG004A has shown early clinical activity in heavily pretreated pancreatic cancer and is being evaluated in a randomized Phase III study in advanced pancreatic cancer.

Targets

F3 (Tissue factor)

Beyond the preview

Go deeper on MRG004A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRG004A.

Explore the full profile